Klencke Barbara
Insider CIK 1647647 · DNAI Chief Medical Officer · XNCR Director · TCRX Director · ALXO Chief Medical Officer, Director · EFTR Director
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| XNCR Xencor Inc | A Award deriv | 2026-06-16 | 2026-07-08 | 20,604 | — | $0 | 20,604 | SEC↗ |
| XNCR Xencor Inc | A Award | 2026-06-16 | 2026-07-08 | 10,302 | — | $0 | 29,974 | SEC↗ |
| TCRX TScan Therapeutics, Inc. | A Award deriv | 2026-05-20 | 2026-05-22 | 67,000 | — | $0 | 67,000 | SEC↗ |
| ALXO ALX ONCOLOGY HOLDINGS INC | A Award deriv | 2026-04-16 | 2026-04-17 | 100,000 | — | $0 | 100,000 | SEC↗ |
| ALXO ALX ONCOLOGY HOLDINGS INC | A Award deriv | 2026-03-03 | 2026-03-05 | 700,000 | — | $0 | 700,000 | SEC↗ |
| ALXO ALX ONCOLOGY HOLDINGS INC | A Award deriv | 2025-09-17 | 2025-09-19 | 300,000 | — | $0 | 300,000 | SEC↗ |
| TCRX TScan Therapeutics, Inc. | A Award deriv | 2025-06-30 | 2025-07-02 | 67,000 | — | $0 | 67,000 | SEC↗ |
| XNCR Xencor Inc | A Award deriv | 2025-06-12 | 2025-06-16 | 27,372 | — | $0 | 27,372 | SEC↗ |
| XNCR Xencor Inc | A Award | 2025-06-12 | 2025-06-16 | 13,686 | — | $0 | 19,672 | SEC↗ |
| ALXO ALX ONCOLOGY HOLDINGS INC | A Award deriv | 2025-01-21 | 2025-01-23 | 40,400 | — | $0 | 40,400 | SEC↗ |
| TCRX TScan Therapeutics, Inc. | P Buy | 2024-09-23 | 2024-09-24 | 5,000 | $5.29 | $26.4K | 45,000 | SEC↗ |
| TCRX TScan Therapeutics, Inc. | P Buy | 2024-08-26 | 2024-08-27 | 5,000 | $5.53 | $27.6K | 40,000 | SEC↗ |
| TCRX TScan Therapeutics, Inc. | P Buy | 2024-08-23 | 2024-08-27 | 5,000 | $5.69 | $28.5K | 35,000 | SEC↗ |
| EFTR eFFECTOR Therapeutics, Inc | A Award deriv | 2024-06-13 | 2024-06-13 | 800 | — | $0 | 800 | SEC↗ |
| XNCR Xencor Inc | A Award deriv | 2024-06-13 | 2024-06-17 | 11,971 | — | $0 | 11,971 | SEC↗ |
| XNCR Xencor Inc | A Award | 2024-06-13 | 2024-06-17 | 5,986 | — | $0 | 5,986 | SEC↗ |
| TCRX TScan Therapeutics, Inc. | A Award deriv | 2024-06-12 | 2024-06-14 | 47,500 | — | $0 | 47,500 | SEC↗ |
| EFTR eFFECTOR Therapeutics, Inc | A Award deriv | 2024-02-19 | 2024-02-21 | 2,000 | — | $0 | 2,000 | SEC↗ |
| TCRX TScan Therapeutics, Inc. | P Buy | 2023-12-14 | 2023-12-18 | 5,000 | $5.08 | $25.4K | 30,000 | SEC↗ |
| XNCR Xencor Inc | A Award deriv | 2023-09-15 | 2023-09-19 | 40,070 | — | $0 | 40,070 | SEC↗ |
| EFTR eFFECTOR Therapeutics, Inc | A Award deriv | 2023-06-22 | 2023-06-22 | 20,000 | — | $0 | 20,000 | SEC↗ |
| TCRX TScan Therapeutics, Inc. | A Award deriv | 2023-06-13 | 2023-06-15 | 36,524 | — | $0 | 36,524 | SEC↗ |
| TCRX TScan Therapeutics, Inc. | A Award deriv | 2023-04-06 | 2023-04-10 | 9,146 | — | $0 | 9,146 | SEC↗ |
| EFTR eFFECTOR Therapeutics, Inc | A Award deriv | 2023-01-20 | 2023-01-24 | 28,125 | — | $0 | 28,125 | SEC↗ |
| SRRA Sierra Oncology, Inc. | D To issuer deriv | 2022-07-01 | 2022-07-01 | 30,000 | — | $0 | 0 | SEC↗ |
| SRRA Sierra Oncology, Inc. | D To issuer deriv | 2022-07-01 | 2022-07-01 | 49,000 | — | $0 | 0 | SEC↗ |
| SRRA Sierra Oncology, Inc. | D To issuer deriv | 2022-07-01 | 2022-07-01 | 167,091 | — | $0 | 0 | SEC↗ |
| SRRA Sierra Oncology, Inc. | D To issuer deriv | 2022-07-01 | 2022-07-01 | 4,999 | — | $0 | 0 | SEC↗ |
| SRRA Sierra Oncology, Inc. | D To issuer deriv | 2022-07-01 | 2022-07-01 | 4,508 | — | $0 | 0 | SEC↗ |
| SRRA Sierra Oncology, Inc. | D To issuer deriv | 2022-07-01 | 2022-07-01 | 1,749 | — | $0 | 0 | SEC↗ |
| SRRA Sierra Oncology, Inc. | D To issuer deriv | 2022-07-01 | 2022-07-01 | 11,399 | — | $0 | 0 | SEC↗ |
| SRRA Sierra Oncology, Inc. | D To issuer deriv | 2022-07-01 | 2022-07-01 | 2,061 | — | $0 | 0 | SEC↗ |
| SRRA Sierra Oncology, Inc. | D To issuer deriv | 2022-07-01 | 2022-07-01 | 11,744 | — | $0 | 0 | SEC↗ |
| SRRA Sierra Oncology, Inc. | D To issuer deriv | 2022-07-01 | 2022-07-01 | 50,000 | — | $0 | 0 | SEC↗ |
| SRRA Sierra Oncology, Inc. | D To issuer | 2022-07-01 | 2022-07-01 | 5,000 | $55.00 | $275.0K | 0 | SEC↗ |
| SRRA Sierra Oncology, Inc. | D To issuer | 2022-07-01 | 2022-07-01 | 10,000 | $55.00 | $550.0K | 0 | SEC↗ |
| SRRA Sierra Oncology, Inc. | A Award deriv | 2022-06-17 | 2022-06-17 | 12,250 | — | $0 | 12,250 | SEC↗ |
| EFTR eFFECTOR Therapeutics, Inc | A Award deriv | 2022-06-09 | 2022-06-13 | 20,000 | — | $0 | 20,000 | SEC↗ |
| SRRA Sierra Oncology, Inc. | A Award deriv | 2022-03-14 | 2022-03-14 | 50,000 | — | $0 | 50,000 | SEC↗ |
| SRRA Sierra Oncology, Inc. | A Award deriv | 2022-01-28 | 2022-01-28 | 12,250 | — | $0 | 12,250 | SEC↗ |
| EFTR eFFECTOR Therapeutics, Inc | A Award deriv | 2021-11-01 | 2021-11-02 | 40,000 | — | $0 | 40,000 | SEC↗ |
| SRRA Sierra Oncology, Inc. | A Award deriv | 2021-03-15 | 2021-03-17 | 30,000 | — | $0 | 30,000 | SEC↗ |
| SRRA Sierra Oncology, Inc. | P Buy | 2020-08-18 | 2020-08-18 | 3,325 | $12.25 | $40.7K | 5,000 | SEC↗ |
| SRRA Sierra Oncology, Inc. | P Buy | 2020-08-18 | 2020-08-18 | 5,950 | $12.22 | $72.7K | 10,000 | SEC↗ |
| SRRA Sierra Oncology, Inc. | A Award deriv | 2020-02-25 | 2020-02-27 | 167,091 | — | $0 | 167,091 | SEC↗ |
| SRRA Sierra Oncology, Inc. | P Buy | 2019-08-23 | 2019-08-26 | 108,000 | $0.44 | $47.5K | 162,000 | SEC↗ |
| SRRA Sierra Oncology, Inc. | P Buy | 2019-08-22 | 2019-08-26 | 67,000 | $0.43 | $28.8K | 67,000 | SEC↗ |
| SRRA Sierra Oncology, Inc. | P Buy | 2019-08-22 | 2019-08-26 | 54,000 | $0.45 | $24.3K | 54,000 | SEC↗ |
| SRRA Sierra Oncology, Inc. | A Award deriv | 2019-03-04 | 2019-03-05 | 200,000 | — | $0 | 200,000 | SEC↗ |
| SRRA Sierra Oncology, Inc. | A Award deriv | 2018-03-06 | 2018-03-07 | 180,360 | — | $0 | 180,360 | SEC↗ |
| SRRA Sierra Oncology, Inc. | A Award deriv | 2017-03-06 | 2017-03-08 | 70,000 | — | $0 | 70,000 | SEC↗ |
| DNAI ProNAi Therapeutics Inc | A Award deriv | 2016-09-30 | 2016-10-04 | 456,000 | — | $0 | 456,000 | SEC↗ |
| DNAI ProNAi Therapeutics Inc | A Award deriv | 2016-03-08 | 2016-03-10 | 82,500 | — | $0 | 82,500 | SEC↗ |